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The number of people with diabetes mellitus (DM) continues to 
increase, with projections suggesting a rise from 429 million in 2017 
to 629 million in 2045.[1] It is notable that the greatest increase is 
being seen in low- and middle-income countries, where the peak 
prevalence occurs at a younger age.[2] By implication, an increasing 
number of pregnancies will be affected by DM.
In South Africa (SA), it is estimated that 3.5 million people have 
DM, with many more undiagnosed.[1] Global estimates are that type 
1 DM (T1DM) accounts for ~5 - 10% of people with DM and type 2 
DM (T2DM) for ~90 - 95%.[3] DM2 is frequently undiagnosed until 
pregnancy, and incorrectly labelled as gestational DM (GDM). It is 
believed that women with undiagnosed T2DM carry a much higher 
maternal and fetal risk than those with GDM. In 2008 - 2009, the 
International Association of Diabetes in Pregnancy Study Groups 
(IADPSG) and the American Diabetes Association suggested that 
similar criteria can be used to diagnose T2DM in pregnancy and 
outside of pregnancy.[4]
GDM is defined as ‘glucose intolerance with onset or first 
recognition during pregnancy’.[5] Currently 1 in 7 births are affected 
by GDM globally.[1] Although these pregnancies do not carry the 
same risks as pregestational DM, recent literature has shown that 
babies born to mothers with GDM are hyperinsulinaemic, often 
macrosomic, and at increased risk of shoulder dystocia, birth trauma, 
caesarean delivery and neonatal hypoglycaemia.[6]
GDM furthermore becomes a general public health issue, since 
women with GDM have a 60% probability of developing T2DM later 
in life, with an annual conversion rate of ~10% per year.[7]
Huddle,[8] in his study on the management and outcome of DM 
in pregnancy at Chris Hani Baragwanath Hospital in Johannesburg, 
SA, during 1992 - 2002, reported that patients who booked early and 
were exposed to treatment for the duration of their pregnancies had a 
good pregnancy outcome, similar to those in high-income countries. 
However, late presentation was associated with a very high overall 
perinatal mortality rate (PNMR) of 15.6%, compared with 3.7% for 
the treated group. There were no significant differences between the 
PNMR for T1DM, T2DM and GDM in the treated groups (4.2%, 
3.9% and 2.8%, respectively). The combined PNMR for the treated 
and control groups was 6.3%.
Ekpebegh et al.[9] found a PNMR of 5% in patients with T2DM at 
Groote Schuur Hospital (GSH) in Cape Town, SA. Increased rates 
were directly associated with high booking glycated haemoglobin 
(HbA1c) levels. Interestingly, treatment throughout pregnancy with 
glibenclamide was also associated with increased perinatal mortality, 
although no clear explanation for this could be found. Perinatal 
mortality was not increased in patients treated with metformin.
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Background. The burden of diabetes mellitus (DM) has increased dramatically worldwide. The association between poorly controlled DM 
and poor pregnancy outcomes has been well described.
Objectives. To describe the pregnancy outcomes of patients with pregestational and gestational DM attending Groote Schuur Hospital, 
Cape Town, South Africa.
Methods. A retrospective audit was undertaken of all women with pregestational and gestational DM (GDM) who attended Groote 
Schuur Hospital obstetric care from 1 September 2010 to 31 August 2011. Information routinely collected at booking and during the rest 
of pregnancy was entered onto a data abstraction form. Patients diagnosed with GDM were further subdivided into two groups, GDM and 
impaired glucose tolerance (IGT), depending on the oral glucose tolerance test results.
Results. A total of 725 diabetic pregnancies were managed: 35 women had type 1 DM (T1DM), 194 had type 2 DM (T2DM), 192 had 
GDM and 304 had IGT. The median glycated haemoglobin (HbA1c) value at booking was highest for T1DM, followed by T2DM and lastly 
GDM. Overall, 10.7% of women had pre-existing hypertension and 9.8% developed pre-eclampsia (PET). The preterm delivery rate (before 
38 weeks) was 68.8% for women with T1DM, 38.7% for those with T2DM, 34.9% for those with GDM and 22.4% for those with IGT. The 
caesarean section rate exceeded 50% in all groups. The overall perinatal mortality rate was 2.5% (25/1 000 births) for the study population, 
with T1DM and T2DM contributing most deaths (6.4% and 4.2%). The overall rate of congenital malformations was 2.4% (n=18 cases), but 
the rate was 5.7% for patients with T1DM and 4.6% for those with T2DM.
Conclusion. The audit demonstrated outcomes similar to those in the developed world, with major congenital malformations, unexplained 
stillbirths and PET accounting for the majority of perinatal deaths. Stricter control with the aim of achieving lower or normal HbA1c levels 
before conception may be the only intervention that could bring about change.
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and pregestational DM, and specifically mild GDM, also referred 
to as impaired glucose tolerance (IGT), to assess whether care for 
this group of patients could be downgraded to secondary level. The 
primary outcomes looked at were miscarriages, congenital abnor-
malities, shoulder dystocia, macrosomia and perinatal mortality. 
Maternal outcomes included need for induction of labour, incidence 
of pre-eclampsia (PET), preterm delivery and caesarean section.
Methods
Study design and population
This was a retrospective descriptive study of all patients who attended 
GSH with either pre-existing or newly diagnosed GDM over a 
period of 1 year (1 September 2010 - 31 August 2011). Diabetes 
was considered pregestational if it existed before conception and 
gestational if it was first diagnosed during pregnancy.
At GSH and within its drainage area, the antenatal diabetes 
screening programme calls for screening at 16 weeks’ gestation, and 
again at 24 - 28 weeks if the first test was normal. GDM was diagnosed 
if the patient had a fasting blood glucose level >5.5  mmol/L or a 
2-hour level of >7.8 mmol/L using a 75 g oral glucose tolerance test 
(OGTT). Patients were further divided into two groups based on 
the OGTT results: IGT if the fasting blood glucose level was 5.5 - 
7  mmol/L and the 2-hour value 7.8 - 11 mmol/L, and GDM if the 
fasting level was >7 mmol/L and the 2-hour level >11 mmol/L. For 
the purpose of this article, all patients diagnosed for the first time in 
pregnancy were regarded as having GDM, but data were analysed 
separately for IGT and GDM.
Data collection
Data were entered into a database using Microsoft Office Excel 2007 
(Microsoft, USA). Data captured included past obstetric history, 
type of diabetes, initial HbA1c level, gestational age at booking, 
type of treatment, maternal complications, presence or absence of 
fetal abnormalities, birth weight, level of glucose control, incidence 
of PET, mode of delivery and pregnancy outcome. Data were 
anonymised upon entry into the database.
Statistical analysis
Maternal characteristics, clinical measures and outcomes were 
summarised using descriptive statistics. Continuous variables were 
expressed as medians with interquartile ranges, and categorical 
variables were presented as frequencies and percentages. The 
Kruskal-Wallis test was used to compare differences in non-normally 
distributed continuous variables between DM classification groups. 
The Wilcoxon rank-sum test was used for comparisons of two 
groups where applicable. For associations between categorical 
variables, either Pearson’s χ2 test or Fisher’s exact test was applied 
depending on the distribution of frequencies. A p-value of <0.05 was 
considered statistically significant. Analysis was performed in Stata 
13 (StataCorp, USA).
Ethical considerations
The study protocol was submitted for ethical approval to the Human 
Research Ethics Committee (HREC) of the University of Cape Town 
(ref. no. 377/2012). Consent and institutional approval were obtained 
from GSH as the site of the study, and the database was subsequently 
registered with the HREC (ref. no. R010/2016).
Protocol for clinical management
Pregestational DM
Women with pregestational DM were admitted to a single antenatal 
ward for review and optimisation of treatment. The baseline work-
up included HbA1c levels at booking, serum creatinine, urea and 
electrolytes, and a 24-hour urinary protein test. A fetal ultrasound 
scan to confirm viability and to assess for fetal anomalies was 
performed in patients assessed before 22 - 24 weeks’ gestation. 
Dietary counselling and education on diabetes was provided by a 
trained dietician, as well as nursing and medical staff.
In patients with T2DM all oral therapy other than metformin was 
discontinued, and if target blood glucose levels were not met after 1 
day in hospital (fasting levels <5.5 mmol/L and 2-hour postprandial 
levels <6.7 mmol/L), either insulin was added to the metformin or 
metformin was replaced by insulin, similar to the protocol used by 
Ekpebegh et al.[9]
Patients with T1DM were converted to a multiple daily insulin 
regimen of regular and intermediate-acting insulin. Subsequent 
adjustment of the doses was based on fasting and postprandial values.
GDM (GDM and IGT)
All patients diagnosed with GDM and IGT received dietary 
counselling from a trained dietician, and fasting and postprandial 
glucose levels were assessed. HbA1c was measured if either of the 
two OGTT values fell in the overt diabetic range. If the glycaemic 
targets (fasting glucose <5.5 mmol/L or 2-hour postprandial value 
<6.7 mmol/L) were not achieved, treatment was commenced: first 
metformin, and then insulin if indicated.
All patients on treatment were asked to return 1 week later to 
assess response and compliance. Thereafter, patients were seen at 
a dedicated diabetes clinic fortnightly until 32 weeks, and then 
weekly until delivery at 38 weeks. Ultrasound scans were done at 22 
weeks to screen for fetal anomalies and at 32 and 36 - 37 weeks for 
growth checks. HbA1c levels were repeated at 6 - 8-week intervals 
and delivery was timed for 38 weeks’ gestation. Women were offered 
induction of labour in the absence of an indication for caesarean 
section (CS) and evidence of macrosomia on the ultrasound scan. 
CS was offered if the estimated fetal weight exceeded 4 000 g and the 
abdominal circumference exceeded the 97th centile.
Results
During the study period there were 5 551 deliveries at GSH, which 
provides care for all high-risk pregnancies and 39 203 deliveries in the 
Metro West, the health district that GSH serves as the tertiary level 
hospital. There were 725 DM patients with 740 births at GSH; the 
majority had GDM and IGT (68.6%).
Maternal profiles (Table 1)
The median gestational age at booking was <20 weeks for all the 
groups. Compared with the other three groups, women in the T1DM 
group were younger and had a lower BMI but a higher median 
HbA1c level at booking. More than a third of T1DM patients had an 
initial HbA1c >10% at booking.
A substantial proportion of patients with T1DM (50%) and 41.7% 
of patients with T2DM had a daily urinary protein value >300 mg/d. 
However, no investigations other than routine urinary dipstick 
testing were done to rule out other causes for proteinuria.
Chronic hypertension was found to be most prevalent in the 
T2DM group. The incidence of PET, although not significant, was 
highest in T1DM.
Treatment
As expected, all patients with T1DM received insulin, while 99% of the 
T2DM group and 96% of patients with GDM received either metformin 
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or insulin. A third of patients with IGT received some form of 
treatment: metformin alone, metformin and glibenclamide, or insulin.
There was one maternal death at 25 weeks’ gestational age from 
respiratory failure due to the respiratory virus (H1N1).
The T1DM group had the highest preterm delivery rate, but the 
lowest rate of successful induction of labour. Although the caesarean 
section rate exceeded 50% in all groups, the T1DM group had the 
highest rate.
Fetal and perinatal outcome (Tables 2 and 3)
Of the pregnancies in the T1DM group 5.7% (n=2) ended in 
miscarriage, which was a higher rate than in the other groups. The 
IGT group suffered very few miscarriages (0.3%, n=1).
Fetal anomalies were more common in the T1DM (5.7%, n=2) and 
T2DM (4.6%, n=9) groups than in the GDM and IGT groups, which 
had rates comparable to the general population (1.5%, n=3 and 1.3%, 
n=4, respectively). Similarly, the PNMR was higher in the T1DM and 
T2DM groups (6.4% (n=2) and 4.1% (n=8), respectively) and lower in 
the GDM and IGT groups (both 1.6% (n=3 and n=5)).
The overall PNMR for the study population was 2.5% (25/1 000 
births). The rates for both GDM and IGT were much lower than for 
the pregestational groups, and in fact lower than the background 
PNMR for SA (3.1%) and the Metro West (2.6%).[10]
The macrosomia rate was similar across all the groups. Of the 
5  deliveries that were complicated by shoulder dystocia, 3 had a 
good outcome for the baby. In the remaining 2 cases, one baby born 
to a mother with T1DM had hypoxic ischaemic encephalopathy 
(birth weight 3 675 g). The other baby, born to a mother with GDM, 
sustained a fractured humerus but also had dysmorphic features, 
microcephaly and an absent corpus callosum. This baby weighed 
3 485 g.
Table 3 shows the correlating HbA1c values at booking for the 
different anomalies.
Discussion
The PNMR in the pregestational DM group was higher than that for 
the background population, in contrast to the GDM and IGT groups, 
in which a lower PNMR was observed. The booking HbA1c level for 
the T1DM patients was unacceptably high and almost 6% of these 
patients had miscarriages. The fetal anomaly rate was higher in both 
the T1DM and T2DM groups than in the GDM and IGT groups, 
where the fetal anomaly rate was lower than the background rate.
Although the PNMR differs between countries, it remains 
significantly higher in pregestational diabetes than in non-diabetic 
and gestational diabetes groups, which is in keeping with our 
findings. Our PNMR for the pregestational DM group was similar to 
Table 1.  Summary of maternal characteristics
T1DM (N=35) T2DM (N=194) GDM (N=192) IGT (N=304) p-value
Age at booking (years), median (IQR) 25 (22 - 30) 33 (29 - 36) 32 (28 - 36) 30 (26 - 35) <0.001
GA at booking (weeks) <0.001
<12, n (%) 20 (57.1) 84 (43.3) 58 (30.9) 78 (25.8)
13 - 24, n (%) 12 (34.3) 87 (44.9) 99 (52.7) 185 (61.3)
≥25, n (%) 3 (8.6) 23 (11.9) 31 (16.5) 39 (12.9)
Median (IQR) 11 (7 - 18) 13 (10 - 19) 17 (12 - 22) 15 (12 - 21) <0.001
BMI at booking (kg/m2)* <0.001
<30, n (%) 10 (62.5) 18 (17) 38 (27) 88 (34.9)
>30, n (%) 6 (37.5) 88 (83) 103 (73) 164 (65)
Median (IQR) 27.9 (25.6 - 32.6) 34.8 (31.3 - 40.4) 34.5 (29.7 - 41.0) 32.8 (27.2 - 39.2) <0.001
HbA1c, median (IQR) 8.7 (7.0 - 10.7) 7.6 (6.3 - 8.8) 6.6 (6.1 - 7.5) 5.9 (5.7 - 6.3) <0.001
Chronic hypertension, n (%) 1 (2.9) 39 (20.1) 20 (10.4) 18 (5.9) <0.001
PET, n (%) 7 (20.0) 18 (9.3) 24 (12.5) 22 (7.2) 0.045
DUP >3 g/24 h, n (%)* 17/34 (50.0) 79/189 (41.7) 10/33 (30.3) 2/6 (33.3) 0.404
GA at delivery (weeks), median (IQR) 36 (34 - 38) 38 (36 - 38) 38 (36 - 38) 38 (38 - 39) <0.001
Preterm delivery (<38 weeks), n (%) 24 (68.8) 75 (38.7) 67 (34.9) 68 (22.4) <0.001
CS, n (%) 22 (62.9) 128 (65.9) 112 (58.3) 153 (50.3) 0.006
Successful IOL, n (%) 4 (11.8) 36 (18.6) 52 (27.1) 88 (30.0) 0.015
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; GDM = gestational diabetes mellitus; IGT = impaired glucose tolerance; IQR = interquartile range; GA = gestational age;  
BMI = body mass index; HbA1c = glycated haemoglobin; PET = pre-eclampsia; DUP = daily urinary protein; CS = caesarean section; IOL = induction of labour.
*n varies due to missing values, % varies due to rounding.
Table 2. Fetal and perinatal outcomes for different types of diabetes in pregnancy
T1DM (N=35) T2DM (N=194) GDM (N=192) IGT (N=304)
Miscarriages, n (%) 2 (5.7) 5 (2.5) 7 (3.6) 1 (0.3)
Fetal anomalies, n (%) 2 (5.7) 9 (4.6) 3 (1.5) 4 (1.3)
Stillbirths, n (%) 2 (6.4) 6 (3.1) 1 (0.5) 5 (1.6)
Early neonatal deaths, n (%) 0 2 (1.0) 2 (1.0) 0
PNMR* 6.4 4.1 1.6 1.6
Macrosomia (birth weight >4 000 g), n (%) 3 (8.5) 16 (8.2) 27 (14.1) 28 (9.2)
Shoulder dystocia 1 (3.2) 0 3 (1.5) 1 (0.3)
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; GDM = gestational diabetes mellitus; IGT = impaired glucose tolerance; PNMR = perinatal mortality rate.
*Overall PNMR for the four groups = 2.5%.
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that reported for France in 2001 (4.5%) and higher than reported in 
the UK in 2004 (2.3%). These figures are still much higher than the 
background PNMRs for these countries.[11,12] 
Data on the outcome of IGT, GDM and pregestational DM in SA 
include the studies by Huddle, reporting an overall PNMR of 6.3% 
for pregestational DM,[8] and Ekpebegh et al.,[9] which did not include 
patients with T1DM but reported a PNMR of 5% for T2DM.
Our finding of a higher miscarriage rate in T1DM and higher 
fetal anomaly rates in both T1DM and T2DM is consistent with 
the international literature and probably related to poor glycaemic 
control, as reflected by the high HbA1c values at booking. In our 
study, the HbA1c level in all the T2DM cases with fetal anomalies 
was >8%, which is in keeping with a French survey[11] that found 
significantly higher preterm delivery and congenital anomaly rates if 
the initial HbA1c value was >8%.
These data emphasise the fact that although DM does not feature 
among the top 10 causes of stillbirths in SA, strategies need to be 
employed to decrease the high risk that remains in pregestational 
DM. This is particularly important in view of the fact that DM is 
becoming increasingly common in women of childbearing age in SA. 
In agreement with the conclusion reached in the report of the 2015 
National Pregnancy in Diabetes Audit in England, Wales and the 
Isle of Man,[13] it is essential that attention be given to pre-pregnancy 
counselling in this group. This may prove difficult, because most 
pregnancies in SA are unplanned. Potential solutions include a 
general approach to stricter glycaemic control outside of pregnancy, 
greater attention to addressing family planning in women with 
DM, who generally attend primary care clinics, and finally setting 
up a referral pathway at multidisciplinary clinics in all our major 
centres for women with DM who are planning a pregnancy. These 
clinics would focus on education and optimisation of care, including 
assessment of renal function and degree of retinopathy, ensuring the 
introduction of folate and iron supplementation, a comprehensive 
review of medication that may be teratogenic, and achievement of 
optimal glycaemic control before conception.
One of the main objectives of this study was to determine the 
outcome for IGT and establish whether care for this group of patients 
could safely be downgraded to secondary level. Following the initial 
results, which confirmed excellent outcomes in this group of patients, 
care was indeed downgraded to secondary level. A random blood 
glucose (RBG) measurement is done at every visit, and patients are 
only referred to tertiary care for formal fasting and postprandial 
readings if the RBG is >6.7 mmol/L. This strategy is also employed in 
other countries, where care is downscaled even further to midwife or 
general practitioner level, and is deemed to be safe.[14]
It is likely that at least 40% of our patients diagnosed with GDM 
actually had undiagnosed T2DM, as reflected by the booking HbA1c. 
It is notable that almost without exception patients with poor 
outcomes had an HbA1c of >6.5% at booking.
HbA1c is known to be much lower in early and late pregnancy than 
in non-pregnant women. What appears to be a ‘normal’ HbA1c value 
is therefore in fact a high value for pregnancy.[15]
Although compared with the IGT group more patients with GDM 
required treatment, the number of fetal abnormalities, the rate of PET 
and the PNMR were similar between the two groups and better than 
the rates for T1DM and T2DM. The finding of similar outcomes for 
the GDM and IGT groups was surprising. One reason for this could 
be that the OGTT was done earlier at 16 weeks in all patients who 
qualified for screening, which led to earlier diagnosis and therefore 
earlier initiation of treatment. Treatment was also stepped up 
aggressively if target glucose levels were not maintained. More than 
90% of patients with GDM were treated either with metformin (and 
additional glibenclamide in a few cases) or with insulin.
The rate of PET is reported to be increased in pregestational 
diabetes in the literature, but we found this to be true only for the 
T1DM group in our population (20.0%). Both GDM and T2DM 
showed no increase above the background incidence of PET in our 
setting. It is widely reported that the background incidence of PET is 
much higher in sub-Saharan Africa than in developed countries,[16] 
but this does not explain why T2DM patients in our population do 
not also have an increased rate.
Another change since 2011 is follow-up of patients with GDM. 
Although patients are still followed up at tertiary level, admission has 
become impossible owing to bed constraints, and dietary counselling 
by the attending doctor, followed a week later with fasting and post-
breakfast finger-prick blood glucose levels, is done on an outpatient 
basis. If these are high, oral treatment is commenced and admission 
arranged to establish whether insulin is required. This new regimen 
could potentially lead to significant delay in treatment compared with 
the previous situation.
The IADPSG has in the meantime published new criteria for the 
diagnosis of GDM.[4] It should be noted that neither GSH nor the 
Western Cape Province nor the SA national guidelines have adopted 
these new guidelines as yet.
Study limitations
Our study had several limitations. This was a retrospective review 
and the number of patients with T1DM included was small. In 
addition, knowing the gestational age at which the OGTT was done 
would have added valuable information in terms of classification of 
type of DM and determining reasons for poor outcome.
Table 3. Spectrum of fetal anomalies and HbA1c values at 
booking (where available)
Fetal anomaly HbA1c (%)
T1DM
Univentricular heart 11.7
Multicystic dysplastic kidney 6.7
T2DM
Trisomy 18 9.4
Holoprosencephaly 10.3
Cleft palate, skeletal abnormality 11.9
Encephalocele 11.7
Hypoplastic left heart 10.5
Ventricular septal defect, normal karyotype 8.1
Multicystic dysplastic kidney 12
Ventriculomegaly 12.4
Congenital cystic adenoid malformation 8.2
GDM
Multiple abnormalities 6.4
Pelvic cyst -
Semilobar holoprosencephaly 8.5
IGT
Ventriculomegaly -
Cardiac abnormality -
Congenital cystic adenoid malformation -
Ventricular septal defect, truncus arteriosus -
45,XX Robertsonian translocation -
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; GDM = gestational 
diabetes mellitus; IGT = impaired glucose tolerance.
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Conclusions
These results indicate the need for active family planning and 
optimisation of glycaemic control in women with DM of childbearing 
age. Furthermore, we suggest that women diagnosed with IGT in 
pregnancy, can be managed safely at secondary-level care. Further 
audits on outcome, especially in the GDM and IGT groups, are 
therefore extremely important to ensure that the changes brought 
about have not compromised care.
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